Advertisement
Advertisement
RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
3.56
USDSponsored
-0.08
-2.34%
Mar 05, 15:58 UTC -5
Closed
After-Market
3.55
-0.01
-0.14%
RXRX Earnings Reports
Positive Surprise Ratio
RXRX beat 12 of 19 last estimates.
63%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$17.81M
/-$0.27
Implied change from Q4 25 (Revenue/ EPS)
-49.89%
/+28.57%
Implied change from Q1 25 (Revenue/ EPS)
+20.78%
/-46.00%
Recursion Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue
On Feb 25, 2026, RXRX reported earnings of -0.21 USD per share (EPS) for Q4 25, beating the estimate of -0.32 USD, resulting in a 34.78% surprise. Revenue reached 35.54 million, compared to an expected 25.08 million, with a 41.71% difference. The market reacted with a +6.80% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 17.81 million USD, implying an increase of 28.57% EPS, and decrease of -49.89% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.62
Actual
-$0.92
Surprise
-47.84%
CorMedix Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.83
Actual
$0.61
Surprise
-26.73%
REGENXBIO Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.97
Actual
-$1.30
Surprise
-33.31%
Lexicon Pharmaceuticals, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.18%
Contineum Therapeutics, Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.49
Surprise
-18.41%
Verastem, Inc.
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.53
Actual
-$0.50
Surprise
+7.32%
Lineage Cell Therapeutics, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.05
Actual
$0.00
Surprise
+100.00%
Atea Pharmaceuticals, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.56
Surprise
-5.44%
Liquidia Corporation Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.18
Actual
$0.15
Surprise
-18.48%
Aligos Therapeutics, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$1.88
Actual
-$1.91
Surprise
-1.11%
FAQ
What were Recursion Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Recursion Pharmaceuticals, Inc. Class A Common Stock reported EPS of -$0.21, beating estimates by 34.78%, and revenue of $35.54M, 41.71% above expectations.
How did the market react to Recursion Pharmaceuticals, Inc. Class A Common Stock's Q4 2025 earnings?
The stock price moved up 6.8%, changed from $3.53 before the earnings release to $3.77 the day after.
When is Recursion Pharmaceuticals, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Recursion Pharmaceuticals, Inc. Class A Common Stock's next earnings report?
Based on 7
analysts, Recursion Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of -$0.27 and revenue of $17.81M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement